SUMMARY Eighty-five adults with horizontal concomitant strabismus were treated with an injection of a low dose of botulinum toxin A (BTXA) into the lateral or medial rectus muscle. The ocular deviation was reduced by an average of 60% independently of its size and whether or not surgery had previously been performed. The change was temporary, however, except in those cases with binocular functions, when fusion was re-established. Repeated low dose injections can maintain the improvement, but at higher doses, although larger reductions are produced, temporary local side effects-ptosis and vertical strabismus-are common. The technique is simple, well tolerated, and has no systemic side effects.
Most adults considered for strabismus surgery have long-standing unsightly ocular deviations associated with amblyopia, no demonstrable binocular functions, and a history of one or more eye muscle operations in childhood. ' The short term effect of further surgical treatment is unpredictable, and may reduce eye movements, while in the long term the strabismus frequently recurs. 2 The concept of chemically modifying extraocular muscle function in such circumstances is attractive, and botulinum toxin A has the necessary chemical and biological properties. Its manufacture and quantitation have been standardised, and animal experiments have established that an appropriate dose injected directly into a skeletal muscle causes local paralysis without systemic toxicity.34 Individual extraocular muscles can be selectively weakened in the rhesus monkey, producing a strabismus, and although the treated muscles recover full function there is a permanent change in the ocular alignment.5 The toxin is immunologically inert at the doses used and can be repeatedly injected.6
The clinical application of botulinum toxin A was established in 1980 by Scott, 7 who showed that an extraocular muscle in a patient with strabismus can be effectively weakened under local anaesthesia, allowing the deviated eye to move into alignment.
Several hundred patients ranging in age from 5 months' to 80 years have since been treated in the Patients, materials, and methods Eighty-five patients aged 18 to 72 scheduled for surgery for horizontal concomitant strabismus accepted the alternative of treatment with botulinum toxin injections (Table 1) . Informed consent was obtained, and the patients reserved the right to withdraw from the trial or ask for surgical treatment Botulinum toxin A in ampoules containing 0*05 ,ug freeze dried neurotoxin bound to haemagglutinin was reconstituted with 1-0 ml preservative-free sterile saline, and then diluted to give either 3-12x 10-4 jg or 1-56x10-3 jig of neurotoxin in 0-1 ml of solution. Amethocaine 1% local anaesthetic, 4 drops, was instilled in the conjunctival sac, and adrenaline 0-25%, 1 drop, to constrict the conjunctival vasculature and allow the extraocular muscle to be easily seen. The toxin was injected through a 27 gauge needle with polytetrafluoroethylene insulation except at the tip, which constituted the active electrode of a differential pair, the reference and ground electrodes being standard silver:silver chloride electrodes taped to the brow, with the reference electrode over the eye to be treated. The needle tip was passed through the conjunctiva, then posteriorly alongside the muscle until the equator of the globe was passed, when it was angled into the muscle.9 An electromyographic (EMG) signal was recorded from the needle tip and allowed the appropriate muscle to be identified when activated by the patient's voluntary gaze.
All patients were treated with a dose of 3-12x 10-4 jtg neurotoxin into the muscle (lateral or medial rectus) responsible for the deviation of the eye; orthoptic measurements were repeated at one, inadequate, after its paretic effect had worn off, 1-56x 10-' ,ug neurotoxin was injected into the same muscle and the follow-up schedule repeated. When the appropriate dose of neurotoxin for the individual patient had been established, injections were repeated if the strabismus recurred to a cosmetically unsightly extent.
STATISTICAL ANALYSIS
Stepwise regression was used to determine whether any other variables could help to explain the initial angle of the strabismus or any changes in the angle. The initial angle and both the actual and proportional changes at one, two, four, and eight weeks were chosen as dependent variables. The age and sex of the patients, the direction of the strabismus (esotropia or exotropia), and previous surgery were used as explanatory variables. The initial size was also used as an explanatory variable when the changes in strabismus were used as dependent variables. A partial F ratio of 4 was used to determine inclusion and exclusion of variables in the model.
Results
From March to December 1983, 85 patients were enrolled in the study. The ocular deviations were large, with a high incidence of amblyopia and attempted surgical correction, and binocular functions were demonstrable in only two ( Table 1 ). The size of the initial strabismus was related to the age of patients, with older patient having larger deviations (Fig. 1) . Stepwise regression showed that no other explanatory variable had any effect. The ocular deviation was regarded as abolished if over the period of follow-up the cover test was The maximum change in the angle of the sti mus after one injection occurred at two and weeks, and averaged 34 prism dioptres (Tab but was larger in patients with larger pretreat angles (Fig. 2) . No change in the angle was recc in two cases after treatment; the injection ha been made into the muscle, however, sinc weakness was produced. The proportional ch was relatively constant and averaged 60% o original deviation (Fig. 3) . The sex of the pati the direction of the deviation, and previous su had no influence on the findings. At this stage th movements and saccadic velocity in the directi action of the injected muscle were reduced. proportional reduction in strabismus lessened the next six weeks (Fig. 3) (Fig. 4B) . Six weeks after the injection nearly full right adduction had returned, and at 12 weeks no abnormality of the oculomotor system was detectable (Fig. 4C) . In eight cases the deviation was reduced to an extent acceptable to the patient. Follow-up measurements have shown a gradual return to the pretreatment strabismus over three months. Eight of the remaining 75 patients declined any further treatment, while two accepted surgery and 65 further injections. Twenty-one patients were treated on the high dose schedule; they were older and had larger squints than those on the low dose schedule. The maximum change in the angle of strabismus achieved on the second injection into the previously treated muscle averaged 38-5 prism dioptres. There was a high incidence of temporary partial ptosis and vertical muscle underaction due to orbital spread of BTXA from the treated muscle (Table 3 Two factors probably contribute to the sustained response: during the period of induced paralysis the ipsilateral antagonist rectus muscle develops contracture changes analogous to those sometimes seen in the medial rectus in cases of temporary lateral rectus palsy.'4 At the same time, even after full recovery from the paralysis, there is a permanent disturbance of the pattern of motor innervation in the treated muscle.'5 After repeated injections, the neuromuscular balance between the two opposing horizontal rectus muscles may be altered in favour of the untreated muscle and the strabismus reduced.
Surgical treatment of the patients in this study (average deviation 50 prism dioptres) would involve operating on two or three horizontal rectus muscles under general anaesthetic. Botulinum toxin treatment is shown here to be a safe and simple alternative, effective in younger patients with moderate to large strabismus. Longer follow-up will further define its therapeutic role.
